Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Y K Onno Teng's publication output changed over time?
ScholarIQpublication output · 2007–2023
Output grew100% over the shown period — from 1 works in 2007 to 2 in 2023.
1
1
1
1
2
3
2
2007201620172018202020212023
What are the most-cited papers on Y K Onno Teng?
ScholarIQmost cited works
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie, Brad H. Rovin, Frédéric Houssiau, Ana Malvar, Y K Onno Teng, Gabriel Contreras, Zahir Amoura, Xueqing Yu, Chi-Chiu Mok, Mittermayer B. Santiago, Amit Saxena, Yulia Green, Beulah Ji, C. Kleoudis, Susan W. Burriss, Carly Barnett, David A. Roth
New England Journal of Medicine. 20201,005 CitationsOPEN ACCESS
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, Martin Aringer, Laurent Arnaud, Sang‐Cheol Bae, John Boletis, Ian N Bruce, Ricard Cervera, Andrea Doria, Thomas Dörner, Richard Furie, Dafna D. Gladman, Frédéric Houssiau, Luís Inês, David Jayne, Marios Kouloumas, László Kovács, Chi Chiu Mok, Eric F. Morand, Gabriella Moroni, Marta Mosca, Johanna Mücke, Chetan Mukhtyar, György Nagy, Sandra Navarra, Ioannis Parodis, José María Pego‐Reigosa, Michelle Petri, Bernardo A. Pons‐Estel, Matthias Schneider, Josef S Smolen, Elisabet Svenungsson, Yoshiya Tanaka, Maria G. Tektonidou, Y K Onno Teng, Anǵela Tincani, Edward M Vital, Ronald van Vollenhoven, Chris Wincup, George Βertsias, Dimitrios T. Boumpas
Annals of the Rheumatic Diseases. 2023995 CitationsOPEN ACCESS
2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis
Antonis Fanouriakis, Myrto Kostopoulou, Kim Cheema, Hans‐Joachim Anders, Martin Aringer, Ingeborg M. Bajema, John Boletis, Eleni Frangou, Frédéric Houssiau, Jane Hollis, A. Karras, Francesca Marchiori, Stephen D. Marks, Gabriella Moroni, Marta Mosca, Ioannis Parodis, Manuel Praga, Matthias Schneider, Josef S Smolen, Vladimı́r Tesař, Maria Trachana, Ronald van Vollenhoven, Alexandre E. Voskuyl, Y K Onno Teng, Bernadette van Leew, George Βertsias, David Jayne, Dimitrios T. Boumpas
Annals of the Rheumatic Diseases. 2020813 CitationsOPEN ACCESS
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
Bernhard Hellmich, Beatriz Sánchez‐Álamo, Jan Henrik Schirmer, Alvise Berti, Daniël Blockmans, María C. Cid, Julia U. Holle, Nicole Hollinger, Ömer Karadağ, Andreas Kronbichler, Mark A. Little, Raashid Luqmani, Alfred Mahr, Peter A. Merkel, Aladdin J Mohammad, Sara Monti, Chetan Mukhtyar, Jacek Musiał, Fiona Price-Kuehne, Mårten Segelmark, Y K Onno Teng, Benjamin Terrier, Gunnar Tómasson, Augusto Vaglio, Dimitrios Vassilopoulos, Peter Verhoeven, David Jayne
Annals of the Rheumatic Diseases. 2023704 CitationsOPEN ACCESS
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Brad H. Rovin, Y K Onno Teng, Ellen M. Ginzler, Cristina Arriens, Dawn J. Caster, Juanita Romero‐Díaz, Keisha L. Gibson, Joshua M. Kaplan, Laura Lisk, Sandra Navarra, Samir V. Parikh, Simrat Randhawa, Neil Solomons, Robert B. Huizinga
The Lancet. 2021619 Citations
Related on ScholarIQ
Leiden University Medical Center
Institution
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Paper
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Paper
2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis
Paper
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
Paper
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Paper